We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

BLOOMINGTON– Lilly Endowment Inc., through the eighth phase of its Giving Indiana Funds for Tomorrow (GIFT VIII) initiative, has awarded a $7,834,000 Community Leadership ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly & Co. faced a skeptical Seventh Circuit Tuesday in arguing a lower court used a misplaced two-step process when it ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...